NCT06641154View on ClinicalTrials.gov

Gene Therapy for Crigler Najjar Syndrome Type I (AlphaCN)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2029

Conditions
Crigler-Najjar Syndrome Type I
Interventions
DRUG

GT-UGT1A1-AAV8-02

Intravenous infusion, single dose

Trial Locations (2)

Unknown

RECRUITING

Alphaviva LLC, Moscow

RECRUITING

Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare, Moscow

All Listed Sponsors
lead

Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare

OTHER_GOV